SQLite Web: event_store.db

Could not fetch row with primary-key sig_78f9222558f6.

Update row sig_04e1c421d82a in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.nasdaq.com/articles/heres-why-agios-pharmaceuticals-crashed-23-today","as_of":"2026-04-20T17:15:12.787981+00:00","canonical_url":"https://www.fool.com/investing/2026/04/20/heres-why-agios-pharmaceuticals-crashed-23-today/","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/heres-why-agios-pharmaceuticals-crashed-23-today","article_chars":3742,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_1684d53a5f2797dd","canonical_host":"fool.com","canonical_is_aggregator":false,"canonical_url":"https://www.fool.com/investing/2026/04/20/heres-why-agios-pharmaceuticals-crashed-23-today/","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-21T03:04:28.614930+00:00","extraction_method":"trafilatura","fetched_description":"Key PointsAgios Pharmaceuticals shares dropped 23% following Novo Nordisk's trial results.","fetched_title":"Here's Why Agios Pharmaceuticals Crashed 23% Today | Nasdaq","final_url":"https://www.nasdaq.com/articles/heres-why-agios-pharmaceuticals-crashed-23-today","html_truncated":false,"paywall_likely":false,"publisher_domain":"fool.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/heres-why-agios-pharmaceuticals-crashed-23-today","source_event_id":"evt_a077a74129d9","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"fp":"daa4177d6c22d726","kind":"unusual_volume","published_at":"2026-04-20T16:39:21+00:00","publisher_domain":"fool.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.74,"dates_mentioned":["late 2026","November","second half of 2026","April 20, 2026"],"entities":[{"asset_class":"equity","name":"Agios Pharmaceuticals","relevance":"high","symbol":"AGIO","type":"company"},{"asset_class":"equity","name":"Novo Nordisk","relevance":"high","symbol":"NVO","type":"company"},{"asset_class":"other","name":"etavopivat","relevance":"high","symbol":"","type":"drug"},{"asset_class":"other","name":"mitapavit","relevance":"high","symbol":"","type":"drug"},{"asset_class":"other","name":"FDA","relevance":"medium","symbol":"","type":"regulator"}],"event_type":"price_action","information_gaps":["Unusual volume details are missing: no baseline volume, no volume ratio vs average, and no direction beyond the 23% price drop.","The signal is described as \u201cdiscovery_unusual_volume_delta,\u201d but the provided text does not include any volume metrics or confirmation status for unusual volume.","No explicit statement whether the 23% move is confirmed by additional news sources beyond the article\u2019s attribution to Novo\u2019s trial results.","Catalyst hypothesis for the volume delta cannot be determined from the text because volume data is not provided."],"key_facts":["AGIO shares were down 23% as of 11 a.m. today.","The article attributes the move to Novo Nordisk\u2019s reported results.","Novo\u2019s etavopivat met both co-primary endpoints in the Phase 3 HIBISCUS trial, according to Novo\u2019s release.","The article states Novo plans to file for FDA approval in late 2026.","The article contrasts Agios\u2019 Phase 3 mitapavit results released in November, stating it did not show a statistically significant improvement in its primary endpoint (annualized rate of sickle cell pain crises) versus placebo.","The article says Novo reported \u201ctime to first\u201d VOC of 38.4 weeks in the treatment group vs 20.9 weeks in the placebo group.","The article characterizes Novo\u2019s intent to file as a threat to Agios\u2019 earnings potential and describes Agios\u2019 path to approval as longer and more uncertain."],"numeric_claims":[{"label":"AGIO price drop","value":"23% (as of 11 a.m. today)"},{"label":"Time to first VOC (Novo etavopivat)","value":"38.4 weeks"},{"label":"Time to first VOC (placebo)","value":"20.9 weeks"}],"primary_claim":"Agios Pharmaceuticals shares dropped 23% as of 11 a.m. today following Novo Nordisk\u2019s Phase 3 trial results for etavopivat.","relevance_score":0.78,"sentiment":"negative","source_quality":"high","summary":"Agios Pharmaceuticals (NASDAQ: AGIO) fell about 23% intraday after Novo Nordisk reported Phase 3 results for etavopivat in sickle cell disease. The article frames Novo\u2019s data and planned late-2026 FDA filing as a threat to Agios\u2019 mitapavit market potential.","topics":["sickle cell disease","Phase 3 trial results","etavopivat vs mitapavit","FDA approval timeline","stock price move"]},"source":"Nasdaq Markets","source_domain":"fool.com","summary":"Key PointsAgios Pharmaceuticals shares dropped 23% following Novo Nordisk's trial results.","tickers":[],"title":"Here's Why Agios Pharmaceuticals Crashed 23% Today","url":"https://www.fool.com/investing/2026/04/20/heres-why-agios-pharmaceuticals-crashed-23-today/"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel